Connect with us

Mergers & Acquisitions

Microsoft claims AI diagnostic tool can outperform doctors

Published

on


Unlock the Editor’s Digest for free

Microsoft has built an artificial intelligence-powered medical tool it claims is four times more successful than human doctors at diagnosing complex ailments, as the tech giant unveils research it believes could speed up treatment.

The “Microsoft AI Diagnostic Orchestrator” is the first initiative to come out of an AI health unit formed last year by Mustafa Suleyman with staff poached from DeepMind, the research lab he co-founded and which is now owned by rival Google.

In an interview with the Financial Times, the chief executive of Microsoft AI said the trial was a step on the path to “medical superintelligence” that could help solve staffing crises and long waiting times for overstretched health systems.

Microsoft’s new system is underpinned by a so-called “orchestrator” that creates virtual panels of five AI agents acting as “doctors” — each with a distinct role, such as coming up with hypotheses or choosing diagnostic tests — which interact and “debate” together to choose a course of action.

To test its capabilities, “MAI-DxO” was fed 304 studies from the New England Journal of Medicine (NEJM) that describe how some of the most complicated cases were solved by doctors. 

This allowed researchers to test if the programme could figure out the correct diagnosis and relay its decision-making process, using a new technique called “chain of debate”, which makes AI reasoning models give a step-by-step account of how they solve problems.

Microsoft used leading large language models from OpenAI, Meta, Anthropic, Google, xAI and DeepSeek. The orchestrator made all LLMs perform better, but worked best with OpenAI’s o3 reasoning model to correctly solve 85.5 per cent of the NEJM cases.

That compared with about 20 per cent by experienced human doctors, but those physicians were not allowed access to textbooks or to ask colleagues in the trial, which could have increased their success rate.

A version of the technology could soon also be deployed in Microsoft’s Copilot AI chatbot and Bing search engine, which handle 50mn health queries a day.

Suleyman said Microsoft is nearing “AI models that are not just a little bit better, but dramatically better, than human performance: faster, cheaper and four times more accurate”.

“That is going to be truly transformative,” he added.

Suleyman’s new effort comes after DeepMind has led the way on AI-related healthcare breakthroughs. The Google lab’s chief Sir Demis Hassabis jointly won a chemistry Nobel Prize last year for using AI to unlock the biological secrets of proteins that underpin life. 

Microsoft has invested almost $14bn into OpenAI and has exclusive rights to use and sell its technology. However, the tech giant is embroiled in high-stakes brinkmanship with the start-up, which is attempting to convert into a for-profit entity, with both sides clashing over the future terms of their partnership.

Suleyman said that while OpenAI’s model performed the best, Microsoft was “agnostic” over which of the four “world-class models” MAI-DxO used. 

“We have long believed that they’ll become commodities . . . it’s the aggregate orchestrator which I think is the differentiator,” he said.

Dominic King, the former head of DeepMind’s health unit who joined Microsoft late last year, said that the programme had “performed better than anything we’ve ever seen before” and that “there is an opportunity here today to act almost as a new front door to healthcare”.

The AI models were also prompted to be cost-conscious, which significantly cut the number of tests required to get to a correct diagnosis in the trial, saving hundreds of thousands of dollars in some cases, he said.

However, King stressed that the technology was still in its early stages, had not been peer reviewed and was not yet ready for a clinical environment.

“This is a landmark study,” said Eric Topol, a cardiologist and founder and director of the Scripps Research Translational Institute. “While this work was not done in the setting of real world medical practice, it is the first to provide evidence for the efficiency potential of generative AI in medicine — accuracy and cost savings.”



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Mergers & Acquisitions

FTAV’s further reading

Published

on



AI and jobs; Oklahoma and towers; India and retailers; AI and cybercrime; Norway and elections



Source link

Continue Reading

Mergers & Acquisitions

Trump Intel deal designed to block sale of chipmaking unit, CFO says

Published

on


Unlock the White House Watch newsletter for free

The Trump administration’s investment in Intel was structured to deter the chipmaker from selling its manufacturing unit, its chief financial officer said on Thursday, locking it into a lossmaking business it has faced pressure to offload.

The US government last week agreed to take a 10 per cent stake in Intel by converting $8.9bn of federal grants under the 2022 Chips Act into equity, the latest unorthodox intervention by President Donald Trump in corporate America.

The agreement also contains a five-year warrant that allows the government to take an additional 5 per cent of Intel at $20 a share if it ceases to own 51 per cent of its foundry business — which aims to make chips for third-party clients.

“I don’t think there’s a high likelihood that we would take our stake below the 50 per cent, so ultimately I would expect [the warrant] to expire,” CFO David Zinsner told a Deutsche Bank conference on Thursday.

“I think from the government’s perspective, they were aligned with that: they didn’t want to see us take the business and spin it off or sell it to somebody.”

Intel has faced pressure to carve off its foundry business as it haemorrhages cash. It lost $13bn last year as it struggled to compete with rival TSMC and attract outside customers.

Zinsner’s comments highlight how the deal with the Trump administration ties the company’s hands.

Analysts including Citi, as well as former Intel board members, have called for a sale — and Intel has seen takeover interest from the likes of Qualcomm.

Intel’s board ousted chief executive Pat Gelsinger, the architect of its ambitious foundry strategy, in December, which intensified expectations that it could ultimately abandon the business.

White House press secretary Karoline Leavitt told reporters on Thursday the deal was being finalised. “The Intel deal is still being ironed out by the Department of Commerce. The T’s are still being crossed, the I’s are still being dotted.”

Intel received $5.7bn of the government investment on Wednesday, Zinsner said. The remaining $3.2bn of the investment is still dependent on Intel hitting milestones agreed under a Department of Defense scheme and has not yet been paid.

He said the warrants could be viewed as “a little bit of friction to keep us from moving in a direction that I think ultimately the government would prefer we not move to”.

He said the direct government stake could also incentivise potential customers to view Intel on a “different level”.

So far, the likes of Nvidia, Apple and Qualcomm have not placed orders with Intel, which has struggled to convince them it has reliable manufacturing processes that could lure them away from TSMC.

As Intel’s new chief executive Lip-Bu Tan seeks to shore up the company’s finances, the government deal also “eliminated the need to access capital markets”, Zinsner explained.

Given the uncertainty over whether Intel would hit the construction milestones required to receive the Chips Act manufacturing grants, converting the government funds to equity “effectively guaranteed that we’d get the cash”.

“This was a great quarter for us in terms of cash raise,” Zinsner added. Intel had also recently sold $1bn of its shares in Mobileye, and was “within a couple of weeks” of closing a deal to sell 51 per cent of its stake in its specialist chips unit Altera to private equity firm Silver Lake, he noted.

SoftBank also made a $2bn investment in Intel last week. Zinsner pushed back against the idea that it had been co-ordinated with the government, as SoftBank chief executive Masayoshi Son pursues an ever-closer relationship with Trump.

“It was coincidence that it fell all in the same week,” Zinsner said.



Source link

Continue Reading

Mergers & Acquisitions

Nuclear fusion developer raises almost $900mn in new funding

Published

on


Unlock the Editor’s Digest for free

One of the most advanced nuclear fusion developers has raised about $900mn from backers including Nvidia and Morgan Stanley, as it races to complete a demonstration plant in the US and commercialise the nascent energy technology.   

Commonwealth Fusion Systems plans to use the money to complete its Sparc fusion demonstration machine and begin work on developing a power plant in Virginia. The group secured a deal in June to supply 200 megawatts of electricity to technology giant Google.

The Google deal was one of only a handful of such commercial agreements in the sector and placed CFS at the forefront of fusion companies trying to perfect the technology and develop a commercially viable machine.

CFS has raised almost $3bn since it was spun out of the Massachusetts Institute of Technology in 2018, drawing investors amid heightened interest in nuclear to meet surging energy demand from artificial intelligence.

“Investors recognise that CFS is making fusion power a reality. They see that we are executing and delivering on our objectives,” said Bob Mumgaard, chief executive and co-founder of CFS. 

New investors in CFS’s latest funding round, which raised $863mn, include NVentures, Nvidia’s venture capital arm, Morgan Stanley’s Counterpoint Global and a consortium of 12 Japanese companies led by Mitsui & Co.

Nuclear fusion seeks to produce clean energy by combining atoms in a manner that releases a significant amount of energy. In contrast, fission — the process used in conventional nuclear power — splits heavy atoms such as uranium into smaller atoms, releasing heat.

CFS is also planning to build the world’s first large-scale fusion power plant in Virginia, which is home to the largest concentration of data centres in the world.

BloombergNEF estimates that US data centre power demand will more than double to 78GW by 2035, from about 35GW last year, and nuclear energy start-ups already have raised more than $3bn in 2025, a 400 per cent increase on 2024 levels.

But experts have warned that addressing the technological challenges to the development of fusion would be expensive, putting into question the viability of the technology.

No group has yet been able to produce more energy from a fusion reaction than the system itself consumes despite decades of experimentation.

“Fusion is radically difficult compared to fission,” said Mark Nelson, managing director of the consultancy Radiant Energy Group, pointing to the incredibly high temperatures and pressures required to combine atoms.

“The hard part is not making fusion reactors. Every step forward towards what may be a dead end economically, looks like something that justifies another billion or a Nobel Prize.



Source link

Continue Reading

Trending